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Cross-Sectional Study on Fecal Carriage
of Enterobacteriaceae with Resistance
to Extended-Spectrum Cephalosporins
in Primary Care Patients
Magdalena T. Nu¨esch-Inderbinen, Helga Abgottspon, Katrin Zurfluh, Hans J. Nu¨esch,
Roger Stephan, and Herbert Ha¨chler
The aim of this study was to gain knowledge of the local epidemiology of extended-spectrum cephalosporin-
resistant bacteria in primary care patients in a Swiss community. Fecal swabs were obtained from 291 primary care
patients. Phenotyping and genotyping methods were used for further characterization of the isolates. Risk factors
associated with carriage of ß-lactam-resistant strains were determined. Extended-spectrum cephalosporin-resistant
Enterobacteriaceae were detected in 15 (5.2%) of the primary care patients. Thirteen isolates were CTX-M producers,
one produced SHV-12, and three carried CMY-2. The pathogenic pandemic clone Escherichia coli ST131 was detected
in 26.6% of the patients. Two patients (13.3%) carried two distinct strains simultaneously. There was a statistically
significant risk of carriage of resistant strains for persons with a history of antibiotic therapy 4 months before
sampling ( p= 0.05), markedly for therapy with ß-lactam ( p= 0.01). Age, gender, or history of hospitalization 4
months before sampling was not a risk factor for the acquisition of resistant bacteria in the analyzed patients. The
relatively low prevalence of extended-spectrum cephalosporin-resistant strains in the community reflects the na-
tionwide restrictive policy of antibiotic prescription as well as local implementation thereof. Nevertheless, our study
shows that a potent antimicrobial resistance reservoir is present in primary care patients.
Introduction
The most important mechanism of antibiotic resistancein Enterobacteriaceae is based on the production of enzymes
that inactivate b-lactam antibiotics, including cephalosporin’s
and monobactams by hydrolyzing their b-lactam ring. These
so-called extended-spectrum b-lactamases (ESBLs) are usually
acquired by horizontal gene transfer and have been detected in
human clinical isolates of Enterobacteriaceae since the early
1990s,24 originally as plasmid-mediated point mutational der-
ivates of the TEM- and SHV-b-lactamase families, and then
increasingly, as environmental originating CTX-M enzymes,15
or other less frequent ESBLs, such as OXA- or PER-ESBLs.6,10
In addition, plasmid-mediated AmpC-type ß-lactamases
(pAmpCs) are increasingly reported worldwide, representing
a new threat to successful antibiotic therapy because they are
not, like ESBLs, susceptible to ß-lactamase inhibitors such as
clavulanic acid or sulbactam, and they possess a wider spec-
trum of the enzymatic activity.16
As a further matter of concern, resistance caused by ESBLs
or pAmpCs is often associated with resistance to other clas-
ses of antibiotics such as fluoroquinolones, aminoglycosides,
and sulfamethoxazole/trimethoprim, resulting in multidrug-
resistant strains.10
Infections due to multidrug-resistant, ESBL-producing,
Gram-negative bacteria are treated with carbapenems (e.g.,
imipenem, ertapenem, or meropenem), which have become
invaluable antimicrobial drugs of last resource for preventing
and treating many life-threatening nosocomial infections.22
Therefore, it is most worrisome to note the emergence and
global dissemination of carbapenem-hydrolyzing ß-lactamases
in Gram-negative bacteria, including Enterobacteriaceae and
nonfermenters.2 Unlike the ESBL- and AmpC-ß-lactamases,
which can be readily classified according to their molecular3 or
functional properties,6 carbapenamases represent a diverse
group of enzymes and remain notoriously difficult to detect.
Hence, the actual prevalence of carbapenemase-producing
strains remains uncertain.22
Enterobacteriaceae, especially Escherichia coli, are key indi-
cator organisms for detecting the occurrence of ESBLs in
humans, animals, and the environment. The rapid dissemi-
nation of different ß-lactamases in clinically important
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bacteria is a serious threat to public health. Local knowledge
of the epidemiology and characterization of resistant strains
is of growing importance. The aim of the present study was
therefore (1) to assess the occurrence of resistance to ex-
tended-spectrum cephalosporins in Enterobacteriaceae har-
bored by a collective of primary care patients in a suburban
community in Switzerland, (2) to characterize such isolates
by antibiotic susceptibility testing, identification of the bla
genes, multilocus sequence typing (MLST), and determina-
tion of phylogenetic groups of E. coli, and (3) determination
of risk factors for fecal carriage of resistant strains.
Materials and Methods
Sample collection
This cross-sectional study constituted a convenience
sample of 291 primary care patients reporting to their
general practitioner in a suburban community in the greater
area of Zu¨rich, Switzerland, during a period of 7 weeks in
May and June 2012, for medical consultation. Fecal swabs
were obtained from adult patients between 23 and 96 years
of age.
Each patient was fully informed of the nature of the
sampling and consent was obtained orally from each indi-
vidual during their consultation with the doctor and before
sampling. Minors and nonregistered patients were excluded
from participation and each patient was sampled once only,
by the practitioner, using a commercial rectal swab tube
containing the Amies transport medium (Copan).
Swabs were numbered consecutively. Each anonymised
number was supplemented with the patient’s age, gender,
histories of hospitalization, and antibiotic therapies during
the 4 months before sampling, and notable comorbidities.
The study was approved by the local ethics committee of
Zu¨rich and is registered as number KEK-StV-Nr. 54/12.
Phenotypical detection of strains resistant
to extended-spectrum cephalosporins
and antimicrobial susceptibility testing
Each swab was incubated for 24 hr at 37C in 10 ml of the
EE Broth (BD) for enrichment. One loopful each of the en-
richment cultures was inoculated onto chromogenic Bril-
liance ESBL agar and Brilliance CRE agar (Oxoid) and
incubated at 37C for 24 hr under aerobic conditions. All
colonies with different chromatism and morphology were
picked from the selective plates and subcultured on sheep
blood agar (Difco laboratories; 5% sheep blood, SB055, Ox-
oid) at 37C for 24 hr. Isolates from the same patient dis-
playing different colony colorations and morphologies were
included. Oxidase-negative isolates were subjected to iden-
tification by API ID 32 E (bioMe´rieux).
Disk susceptibility testing and interpretation were per-
formed using antibiotic disks (Becton Dickinson and Com-
pany), according to the recommendations of the Clinical and
Laboratory Standards Institute (CLSI)9 as well as Etest ESBL
strips (bioMe´rieux).
Characterization of bla genes
The isolates were analyzed by screening for bla genes.
DNA was extracted by a standard heat lysis protocol.
Thereafter, specific primer sets (custom-synthesized by Mi-
crosynth) were used to amplify enterobacterial ß-lactamase-
encoding genes belonging to blaTEM, blaSHV and blaCTX-M
14 and
blaCMY-2,
5,12 the last set supplemented with the following
newly designed primer cmy-dn-3 from the blaCMY-2 down-
stream flanking region: 5¢ATGCGCATGGGATTTTCCTTGC3¢.
Resulting amplicons were purified using the PCR Purification
Kit (QIAGEN) according to the manufacturer’s recommenda-
tions. Custom sequencing was performed by Microsynth and
the nucleotide and protein sequences were analyzed with
Codon Code Aligner V. 3.7.1.1. For database searches, the
BLASTN program of NCBI (www.ncbi.nlm.nih.gov/blast)
was used.
Multilocus sequence typing of ß-lactamase-producing
E. coli
Internal fragments of seven housekeeping genes (adk,
fumC, gyrB, icd, mdh, purA, and recA) were sequenced30 and
alleles and sequence types (ST) were assigned in accordance
with the E. coli MLST website (http://mlst.ucc.ie/).
Determination of phylogenetic groups
in ß-lactamase-producing E. coli
After DNA extraction using a standard heat lysis protocol,
ß-lactamase-producing E. coli isolates were classified by
phylogenetic PCR into four main groups (A, B1, B2, and D),
as described previously.8
Statistical analysis of anonymised patients’ data
Risk factors for fecal carriage were calculated based on the
provided data regarding the patients’ history (age, gender,
history of hospitalization 4 months before sampling, appli-
cation of antibiotics, and history of diverticulitis).
Patients were stratified into three age groups: group 1, 20–
40 years; group 2, 40–60 years; and group 3, > 60 years. Data
on antibiotic therapies were categorized according to anti-
biotic classes and, in the case of ß-lactams, additionally
subdivided into their subgroups.
Statistical values were calculated using the Fischer’s one-
tailed exact test. Statistical significance was set at p£ 0.05.
Results
Study population
The total number of primary care patients included in this
analysis was 291, with a male/female ratio of (165/126), a
mean age of 64.5 years, and a median age of 66 years. Age
ranged from 23 to 96 and comprised the following groups:
group1, 20–40 years (n= 20); group 2, 40–60 years (n = 85);
and group 3 (n = 186). Thirty-four patients had been hospi-
talized at some point during 4 months before participation in
the study. Thirty patients had received antibiotic therapy,
predominantly amoxicillin/clavulanic acid (20 patients),
prescribed by their general practitioner during the same time
scale. Fourteen (4.8%) of the patients had a comorbidity of
confirmed diverticulitis.
Extended-spectrum cephalosporin-resistant Enterobacteriaceae
were detected in 15 (5.2%; 9 male/6 female) of the primary care
patients. Multiple strains were isolated from fecal swabs of 2
patients, one simultaneously carrying two distinct E. coli strains,
and one an E. coli and a Citrobacter youngae strain.
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Risk factors for fecal carriage were calculated based on the
provided data regarding the patients’ history and are sum-
marized in Table 1. Thereby, previous therapy with the
combination compound amoxicillin/clavulanic acid emerged
as the only significant risk factor for subsequent colonization
with cephalosporin-resistant isolates ( p= 0.02). Age, gender,
or history of hospitalization 4 months before sampling was
not a risk factor. Furthermore, diverticulitis as a risk factor
could not be established.
Antimicrobial susceptibility patterns of resistant
isolates
From 291 fecal swabs, 17 isolates were analyzed. Their
identities and antimicrobial susceptibility profiles are shown
in Table 2. When applying CLSI criteria, 9 of 17 isolates (53%)
were resistant to the 3rd generation cephalosporin cefotax-
ime in the disk diffusion test. Elevated minimal inhibitory
concentrations (MIC) to cefotaxime and the 4th generation
cephalosporin cefepime were observed in 70% and 17.6% of
the Enterobacteriacea, respectively, when the E test was uti-
lized. All isolates displaying low MIC values to the carba-
penem antibiotic imipenem.
Coresistance to antibiotics other than ß-lactams was fre-
quent, with 47% resistant to quinolones, 29% to gentamicin,
35% to kanamycin and, ranking highest in the class of the
aminoglycosides, 53% to streptomycin. Tetracycline resis-
tance was detected in 70.6%, and chloramphenicol resistance
in 12% of the strains. The highest rate of resistance was to
sulfamethoxazole, with 82% affected, and followed by 65%
of trimethoprim-resistant isolates.
Distribution of ß-lactamase genes
The identification of the isolates’ bla genes are summarized
in Table 3. Of the detected CTX-M enzymes, seven belonged
to the CTX-M group 1 (to which CTX-M-1 and CXT-M-15
belong) and six belonged to the CTX-M group 9 (to which
CTX-M-14 and CTX-M-27 belong), according to the classifi-
cation of Bonnet.4 In total, 13 (76%) of the analyzed isolates
harbored a CTX-M ß-lactamase (Table 3). The most fre-
quently detected CTX-M enzyme was CTX-M-15, which was
found in four E. coli and one C. youngae isolate, giving rise to
a prevalence of CTX-M-15 in the analyzed Enterobacteriaceae
isolates of 31.3%. CTM-X-15 producers displayed the widest
range of coresistances, compared to other isolates. CTX-M-1
was detected in two E. coli strains (12.5% of the E. coli iso-
lates). Three E. coli (18.8%) harbored CTX-M-14. Three fur-
ther E. coli isolates (18.8%) produced CTX-M-27.
The pAmpC-ß-lactamase CMY-2 was detected in three
E. coli strains (18.8%). These strains displayed few to no
coresistances. SHV-12 was detected in one E. coli stain (6.3%).
Two strains in our study were detected together as mul-
tiple isolates from single patients. One patient was shown to
be a carrier of an E. coli producing CTX-M-14 together with a
CTX-M-15 producing C. youngae. Simultaneous carriage of
two distinct E. coli strains producing CMY-2 was noted from
a further patient.
ST distribution of E. coli isolates
MLST of the E. coli isolates revealed nine different STs
(Table 3). Most isolates belonged to ST131 (four isolates,
Table 1. Risk Factors Influencing Fecal Carriage of Extended-Spectrum
Cephalosporin-Resistant Isolates in Primary Care Patients
Characteristic
No. of
patients
No. of patients
identified as carriers
OR
(95% CI)
p-
Valuea
Age groups of screened patients
Age group 20–40 20 3 3.8 (1.0–14.8) 0.07
Age group 40–60 85 2 0.4 (0.1–1.6) 0.1
Age group > 60 186 10 1.1 (0.4–3.4) 0.5
Gender
Male 165 9 1.2 (0.4–3.3) 0.5
Female 126 6 0.9 (0.3–2.5) 0.5
History of hospitalization 4 months before sampling 34 3 2.0 (0.5–7.4) 0.2
History of antibiotic therapy 4 months before sampling 30 4 3.5 (1.1–11.8) 0.05
Prescribed antibiotic classes 4 months before sampling
ß-lactams 20 4 5.9 (1.7–20.6) 0.01
Macrolides 7 1 3.2 (0.4–28.6) 0.3
Quinolones 4 1 6.5 (0.6–66.5) 0.2
Sulfonamides 1 0 0 0.9
Tetracyclines 1 0 0 0.9
Fosfomycins 1 1 Infinity
Nitroimidazoles 1 0 0 0.9
Prescribed ß-lactam antibiotics 4 months before sampling
Amoxicillin 2 1 19.6 (1.2–330.7) 0.1
Amoxicillin & clavulanic acid 14 3 6.0 (1.5–24.5) 0.02
1st generation cephalosporin 1 0 0 0.9
2nd generation cephalosporin 2 0 0 0.9
3rd generation cephalosporin 1 1 Infinity
History of diverticulitis 14 2 3.4 (0.7–16.7) 0.2
aFisher’s exact probability test (one-tailed); entries for which the p-values were£ 0.05 are in bold type.
OR, odds ratio; CI, confidence interval.
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25%) followed by ST2142 (three isolates, 18.8%). Two isolates
belonged to ST90 (12.5%). Other STs, including the pandemic
clone ST40511 were detected as singletons.
Phylogenetic groups of E. coli isolates
Phylogenetic grouping categorized 50% of the E. coli
strains as belonging to the extraintestinal pathogenic group
B2 (four strains) or D (four strains), as shown in Table 3. The
other 50% of the isolates belonged to commensal groups A
(five strains) and B1 (two strains). One strain, HC281E, could
not be assigned to any of the tested phylogenetic groups.
All four ST131 isolates belonged to the virulent extra-
intestinal phylogenetic group B2. The pandemic clone ST405,
as well as two ST2142 isolates and the isolate ST362 belonged
to the phylogenetic group D.
Both ST90 and ST10 isolates belonged to the commensal
phylogenetic group A, as did one ST2142 isolate. Two further
isolates, ST448 and ST962, were assigned to the commensal
phylogenetic group B1.
No clonal relationship among ß-lactamase producers
CTX-M enzymes were found among a large number of
clonal types (Table 3). CTX-M group 1 enzymes (detected in
seven strains) were in one case (isolate HC171) harbored by
pandemic clone ST131-B2 (CTX-M-15) and in one further
instance (isolate HC200) by pandemic clone ST405-D (CTX-
M-15). All other enzymes of this group were detected in
commensal E. coli strains, or, as in one case, in a C. youngae
(isolate HC14G).
CTX-M group 9 enzymes (from six strains) were detected
in three pandemic ST131-B2 clones harboring CTX-M-14 in
one case, and CTX-M-27 in two cases (isolate HC14B, HC56,
and HC111, respectively). One CTX-M-14 and one CTX-M-27
enzyme were detected in extraintestinal pathogenic phylo-
genetic group D strains (isolates HC247 and HC264, re-
spectively). One CTX-M-14 was harbored by a commensal
E. coli strain (HC267).
Two CMY-2-producing E. coli strains isolated simulta-
neously from the same patient belonged to the extraintestinal
pathogenic phylogenetic group D (isolate HC22E) and to
commensal group B1 (isolate HC22C), respectively. One
blaCMY-2 gene was found in an E. coli isolate, typed as ST814,
which did not belong to any of the tested phylogenetic
groups (isolate HC281E). SHV-12 was detected in a com-
mensal E.coli strain (isolate HC11).
Discussion
One of the major challenges public healthcare systems face
today is the global spread of extended-spectrum cephalo-
sporin-resistant Gram-negative bacteria from the hospital
setting into the community, necessitating collaborative ap-
proaches to antimicrobial surveillance.
An important strategy for monitoring and controlling the
spread of multidrug-resistant pathogens is the determination
of their occurrence in community-based patients. Therefore,
knowledge of the local epidemiology and risk factors is
crucial to estimate the magnitude of the problem.
The fecal carriage rate of extended-spectrum cephalospo-
rin-resistant Enterobacteriaceae in Swiss primary care patients
is 5.2%. This is slightly lower than the rate of 5.8% ESBL-
producing Enterobacteriaceae found in a collective of healthy
factory staff in Switzerland,14 possibly reflecting local or
behavioral differences, such as traveling, which is a known
risk factor for acquiring ESBL-producing E. coli.27 Carriage
rates are lower than those found in primary care patients in
Belgium,20 the Netherlands,25 and Great Britain,29 where
ESBL-producing Enterobacteriacea were detected in 7%, 10%,
and 11% of community-based patients, respectively. For the
Netherlands, a country comparably restrictive in its antibi-
otic prescription policy25 such as Switzerland,13 the unex-
pectedly high rate of carriage seems to be linked to the
country’s high antibiotic use in the poultry industry and
transmission through the food chain.18
Although Switzerland compares relatively favorable to
other European countries, our results show that ESBL-
producing bacteria are indeed present in the community, a
fact that should be taken into account when considering
treatment options.
In our study, the CTX-M enzymes were the most prev-
alent ESBLs. This is consistent with the dissemination
noted for other European countries, with CTX-M-15 the
most common.7,19
The global distribution of CTX-M-15-producing E. coli is
mostly due to the worldwide pandemic uropathogenic clone
ST131-B2,26 and, to a lesser extent, clone ST405-D.11 How-
ever, the CTX-M-15-producing strains identified in this study
belonged to multiple STs and to diverse, commensal as well
as pathogenic phylogenetic groups, or, as in one case, even to
another species C. youngae. Together with the inhomogenous
antibiotic susceptibility patterns of the individual isolates,
one must assume that the dissemination of CTX-M ß-lacta-
mases in the community is driven primarily by the spread of
mobile genetic elements, rather than by clonal dissemination.
Although the finding of 26.6% of clone ST131 in our patient
collective comes close to the rate of previous reports showing
24%,29 we found that E. coli ST131 strains isolated from our
collective were, as opposed to previous reports, not predomi-
nantly CTX-M-15 producers, but harbored by the majority the
group 9 enzymes CTX-M-14 and CTX-M-27. Interestingly,
E.coli ST131 harboring CTX-M-27 in humans are rare in Eur-
ope,21 but have been detected in tertiary care patients in Israel,1
and a very recent study from Japan reported for the first time a
cluster of CTX-M-27-producing E. coli among clinical isolates,17
suggesting that this clone is currently emerging.
At present, pAmpC b-lactamases are being detected
globally with the CMY-2 b-lactamase being the most widely
distributed in Enterobacteriaceae.16 Three of the strains ana-
lyzed in our study harbored CMY-2. All demonstrated clonal
diversity, again suggesting a dissemination of mobile genetic
elements within the community. This is particularly sug-
gestive in the case of a patient with a history of hospitali-
zation exhibiting coexistence of clonally distinct CMY-2-
producing strains, where horizontal transfer of the blaCMY-2
gene appears to have occurred between the hospital-associated
pathogenic phylogenetic group D E. coli and the commensal
group B1 strain.
SHV-12, originally detected in an E. coli hospital strain in
Switzerland23 has disseminated to commensal E. coli strains,
and although rare, appears to persist within the community.
This finding provides further evidence for the propagation of
a resistance gene pool in nonpathogenic bacteria in the
population.
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None of the analyzed strains contained any of the cur-
rently globally disseminating and clinically important car-
bapenem hydrolyzing metallo-ß-lactamases (MBLs) such as
the active-on-imipenem (IMP) type, the verona-integron-en-
coded MBL (VIM) type,28 or the New-Delhi MBL (NDM)
type of MBLs.22
This study offers insight into the antibacterial resistance
gene pool not only in bacterial pathogens, but in opportu-
nistic pathogens and commensal bacteria of the Swiss pop-
ulation. The impact of these potent reservoirs of resistance
genes on public health is not yet sufficiently investigated and
calls for collaborative approaches by the scientific and
medical community.
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